Avadel pharmaceuticals provides corporate update and reports second quarter 2021 financial results

Dublin, ireland, aug. 09, 2021 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (eds) and cataplexy in adults with narcolepsy, today provided a corporate update and announced its financial results for the second quarter ended june 30, 2021.
AVDL Ratings Summary
AVDL Quant Ranking